Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Northeastern University researchers resurrected an extinct plant gene, turning back the evolutionary clock to pave a path forward for the development and discovery of new drugs.

“We are excited to partner with Lisata to investigate how certepetide and the SMARTag ® technology might be used together to make ADCs with enhanced functions,” stated Penelope Drake, Head of R&D, ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Ancient Taiwan jawbone fossil confirms Denisovan presence, expanding their range across East and Southeast Asia regions.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceu tical Co.

Why do problems occur with a special variant of 'protein glues', the split inteins, that severely limit their use in producing proteins? A team has now answered this question.

In a study published in Science, a research team led by Prof. Ye Jian from the Institute of Microbiology of the Chinese ...